Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT03054454
Other study ID # 20720171
Secondary ID
Status Not yet recruiting
Phase N/A
First received February 13, 2017
Last updated February 15, 2017
Start date April 2017
Est. completion date June 2017

Study information

Verified date February 2017
Source South Tees Hospitals NHS Foundation Trust
Contact Emma Scott, Bsc Hons
Phone 01642 854237
Email emma.scott2@nhs.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Observational studies clearly show that people with diabetes and end-stage kidney failure have an increased risk of foot ulceration and leg amputation. However, there is very little evidence on addressing this problem.

Diabetes foot care teams have been shown to reduce hospital admissions, length of stay and leg amputation in people with diabetes. Since their introduction at The James Cook University Hospital (JCUH) major diabetes-related leg amputation rates have fallen by 86 percent (1995 to 2010).

People with diabetes and end-stage kidney failure require haemodialysis (blood cleaning) 3 times per week for several hours each time. This time commitment makes it difficult to attend other clinical appointments. An audit at JCUH shows that this population fails to attend the normal diabetes foot services.

This project aims to reduce the incidence of foot disease in people with diabetes and end-stage kidney failure on dialysis. The investigators will set up a podiatry-led intervention within the dialysis unit to prevent and promptly treat foot disease in this population. This will involve foot risk assessment, risk reduction and treatment during dialysis. The intervention will involve diabetes consultants, podiatrists, vascular and orthopaedic surgeons . In this way the investigators hope to reduce leg amputation, hospital admission, procedures to unblock arteries and death in this high risk group.

The study will run in the dialysis unit at JCUH. Patients will be divided into two groups: those attending for dialysis on a Monday, Wednesday and Friday will form the treatment group and those attending on a Tuesday, Thursday and Saturday will continue to be managed as at present. The investigators will collect data from patient health care records looking in particular at leg amputations, hospital admissions due to foot problems, foot surgery and operations to unblock arteries.


Description:

Diabetes is the largest cause of leg amputation and kidney failure; 15-20% of people with diabetes will have a foot ulcer in their lifetime, with 5-10% having an ulcer at any one time. The history of a foot ulcer in a person with diabetes increases the risk of leg amputation 2-3 fold. A person with diabetes is 23 times more likely to have a leg amputation than a person without diabetes.

The risk of having a foot ulcer is increased by another four times and the risk of leg amputation by a further eight times in people with diabetes and kidney failure on dialysis compared to those with diabetes and normal kidney function. Kidney failure in people with diabetes increased by 56% between 2006 and 2010.

Sixty per cent of people who have diabetes and a leg amputation will be dead within 5 years. Those with end stage kidney failure and a foot ulcer have an even bleaker outcome: only 50% will be alive in 2 years. This reduces to 26% following leg amputation.

An audit in 2014 of the patients attending the dialysis unit at the hospital showed that half had diabetes. Of these, half had had a foot ulcer at some point. Half of these had an ulcer at the time of the audit. Less than one quarter of those with a foot ulcer had been reviewed by the Diabetes Foot Team. National guidance states that all people with diabetes and a foot ulcer should be seen by a diabetes foot team within one working day of the ulcer being detected.

The investigators looked for evidence to show how to reduce the risk of foot problems in people with diabetes and end-stage kidney failure on dialysis but were unable to find any evidence.

Regional kidney and diabetes specialist groups have confirmed that there is no such work to address this problem anywhere in the North East and neither were aware of such an intervention anywhere in the UK.

None of the leading Consultants in the UK working in the field of diabetes-foot disease are aware of the existence of a project like this but were in agreement about the need for one.

The existing literature shows the severity of the problem but not the solution. The investigators plan to provide evidence to show an effective and cost-saving solution to reduce the burden of diabetic foot disease in people with diabetes and end-stage kidney failure People who require dialysis attend the dialysis unit 3 times a week on fixed days and in a fixed session which doesn't tend to change. People with diabetes and kidney failure on dialysis will be divided into 2 groups: a treatment group and a comparator group. The treatment group will be those that have dialysis on a Monday, Wednesday and Friday. The comparator group will be those who have dialysis on a Tuesday, Thursday and Saturday

The comparator group will continue to receive diabetes foot care using the standard model that is in existence at present (i.e. screening at GP practice, podiatry review close to home and referral to a hospital diabetes foot team when necessary)

The treatment group will be reviewed by a podiatrist while they are having dialysis. The Podiatrist will examine their feet at the first meeting and look for diabetic foot problems, if not present, make a standard assessment of the risk of diabetic foot problems developing. Further management will be guided by this assessment.

The population will fall into two groups :those without active foot problems but at high risk of developing foot problems; and those with active foot disease (e.g. foot ulcer). High risk patients without current foot problems will receive a package of treatments aimed at preventing foot ulcers (including education, removal of hard skin, foot and nail care, changes to shoes and the provision of bespoke insoles, creams and further podiatric review.

Those with active foot problems will have investigations and treatment according to individual need, which might include x-rays, tests for bacterial infection, blood tests, removal of hard skin, wound dressings and offloading. Treatments to improve blood supply to the feet and surgical removal of infected tissue might be needed. This will be lead by the podiatrist. However, other members of the diabetes foot care team (MDT) will be involved as required, using the existing weekly diabetes foot MDT meetings as a forum for discussion of the patients. Other MDT members will then also see the patients on the dialysis unit, thus providing patient-centred care.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 32
Est. completion date June 2017
Est. primary completion date May 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria:

- Diabetes Type 1 2, secondary or MODY

- End-stage renal failure (CKD stage 5)

- Routinely attending the dialysis unit at The James Cook University Hospital for regular dialysis

Exclusion Criteria:

- Lack of capacity

- Bilateral lower limb amputees

- People on dialysis who do not have diabetes

Study Design


Intervention

Procedure:
Podiatry
Podiatry treatments and care from the multidisciplinary team.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
South Tees Hospitals NHS Foundation Trust Boehringer Ingelheim

Outcome

Type Measure Description Time frame Safety issue
Primary Nights spent in hospital with a diabetes-related foot problem. Nights spent in hospital with a diabetes-related foot (below ankle) problem (ulceration, cellulitis, foot pain, swelling, foot infection/ osteomyelitis, necrosis, gangrene, blister, ischaemia, fracture) 1 year
Secondary number of below knee amputations attributed to diabetic foot disease the no. of below knee amputations will be recorded in this group and compared tot he comparator group who will receive usual care 1 year
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A